Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

Inclusion Criteria: * Age ≥ 12 years and ≤ 50 years * Glucose 6 phosphate dehydrogenase (G6PD) normal status defined by Carestart rapid diagnostic test or the G6PD qualitative test (OSMMR2000) * Absence of symptomatic falciparum malaria, defined by fever on enrolment * Presence of P. falciparum gametocytes on thick blood film at a density \>16 gametocytes/µL (i.e. ≥ gametocytes recorded in the thick film against 500 white blood cells) * Absence of other non-P. falciparum species on blood film * No allergies to study drugs * No use of antimalarial drugs over the past 7 days (as reported by the participant) * Hemoglobin ≥ 10 g/dL * Individuals weighing \< = 80 kg * No evidence of acute severe or chronic disease * Written, informed consent Exclusion Criteria: * Age \< 12 years or \> 50 years * Women who are pregnant or lactating * Blood thick film negative for sexual stages of malaria * Detection of a non-P. falciparum species by microscopy * Previous reaction to study drugs / known allergy to study drugs * Signs of severe malaria, including hyperparasitemia (defined as asexual parasitemia \> 100,000 parasites / µL) * Signs of acute or chronic illness, including hepatitis * The use of other medication (with the exception of paracetamol and/or aspirin) * Consent not given * G6PD-deficiency by Carestart rapid diagnostic test or the OSMMR2000 G6PD qualitative test * Use of antimalarial drugs over the past 7 days (as reported by the participant) * The use of other medication (with the exception of paracetamol and/or aspirin) * Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically) * Signs of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child Pugh stage B or C) * Signs, symptoms or known renal impairment * Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin \< 10 g/dL, platelets \< 50,000/μl, White Blood Cell count (WBC) \< 2000/μl, serum creatinine \>2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age. * Family history of diseases leading to QT prolongation or recent treatment with drugs linked to QT prolongation * Blood transfusion in the last 90 days. * Consistent with the long half-life of tafenoquine, effective contraception should be continued for 5 half-lives (3 months) after the end of treatment. * History of psychiatric disorders